Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Clinical Development
Biologics
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending T
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Clinical Development
Biologics
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
CureVac
Biotech
GSK's mRNA flu vaccine finally bests tricky B strains in phase 2
After an initial defeat against the biggest barrier to mRNA flu vaccines, GSK has returned with a reformulated candidate that has delivered the goods.
James Waldron
Sep 12, 2024 4:52am
CureVac gains $430M GSK vaccine contract, loses 30% of staff
Jul 3, 2024 5:00am
Xaira, Anthos, CureVac & more—Chutes & Ladders
Apr 26, 2024 8:30am
CureVac, chasing Moderna mRNA flu shot, hits similar problems
Apr 4, 2024 9:30am
CureVac touts COVID-19 vax data despite adverse events
Jan 5, 2024 11:16am
CureVac hand-picks mRNA flu vaccine but keeps data tucked away
Sep 12, 2023 10:45am